Roivant Sciences Ltd. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Roivant Sciences Ltd. (ROIV), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are ROIV insiders buying or selling?
In the last 12 months, Roivant Sciences Ltd. insiders reported 0 open-market purchases ($0) and 43 sales ($805.7M) — net selling of $805.7M. Since March 2022, Trabud has recorded 145 Form 4 filings for ROIV: 2 buys ($20.2M) and 143 sells ($2.2B).
Source: SEC EDGAR Form 4
What stands out
- No Roivant Sciences Ltd. insider made an open-market purchase in the last 12 months; the 43 reported open-market sales totaled $805.7M.
Key Statistics (March 2022 – Oct 5, 2026)
Total Form 4 filings
145
SEC EDGAR
Insider filers
18
Insider buys (2)
$20.2M
Insider sells (143)
$2.2B
Insider sentiment
Net sellingNet insider flow of $2.2B in net selling since March 2022, and $805.7M in net selling over the last 12 months.
Recent ROIV insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | Melissa B, Epperly | Director | Sale | 17.8K | $36.10 | $640.9K | SEC ↗ |
| Oct 2, 2026 | Eric Venker | President & Immunovant CEO | Sale | 200.0K | $36.62 | $7.3M | SEC ↗ |
| Sep 17, 2026 | Melissa B, Epperly | Director | Sale | 4.9K | $39.74 | $196.2K | SEC ↗ |
| Sep 17, 2026 | Meghan Fitzgerald | Director | Sale | 5.1K | $39.74 | $203.2K | SEC ↗ |
| Sep 11, 2026 | Meghan Fitzgerald | Director | Sale | 20.0K | $39.90 | $798.0K | SEC ↗ |
| Sep 2, 2026 | Eric Venker | President & Immunovant CEO | Sale | 200.0K | $35.77 | $7.2M | SEC ↗ |
| Aug 22, 2026 | Mayukh Sukhatme | President & CIO | Sale | 335.2K | $36.88 | $12.4M | SEC ↗ |
| Aug 19, 2026 | Mayukh Sukhatme | President & CIO | Sale | 664.8K | $36.34 | $24.2M | SEC ↗ |
| Jul 30, 2026 | Eric Venker | President & Immunovant CEO | Sale | 200.0K | $34.95 | $7.0M | SEC ↗ |
| Jul 2, 2026 | Meghan Fitzgerald | Director | Sale | 10.0K | $34.90 | $349.0K | SEC ↗ |
| Jul 1, 2026 | Melissa B, Epperly | Director | Sale | 17.8K | $34.38 | $610.3K | SEC ↗ |
| Jul 1, 2026 | Keith S Manchester | Director | Sale | 1.6M | $34.46 | $56.4M | SEC ↗ |
| Jul 1, 2026 | Daniel Allen Gold | Director | Sale | 1.4M | $34.32 | $49.4M | SEC ↗ |
| Jun 30, 2026 | QVT Financial LP | Other | Sale | 1.4M | $34.32 | $49.4M | SEC ↗ |
| Jun 29, 2026 | Mayukh Sukhatme | President & CIO | Sale | 1.0M | $34.11 | $34.1M | SEC ↗ |
| Jun 26, 2026 | Eric Venker | President & Immunovant CEO | Sale | 200.0K | $33.16 | $6.6M | SEC ↗ |
| May 22, 2026 | Eric Venker | President & Immunovant CEO | Sale | 200.0K | $30.27 | $6.1M | SEC ↗ |
| Apr 22, 2026 | Eric Venker | President & Immunovant CEO | Sale | 200.0K | $29.59 | $5.9M | SEC ↗ |
| Apr 20, 2026 | Matthew Gline | CEO | Sale | 289.8K | $29.16 | $8.4M | SEC ↗ |
| Apr 10, 2026 | Jennifer Humes | Chief Accounting Officer | Sale | 13.5K | $28.37 | $384.1K | SEC ↗ |
| Mar 31, 2026 | Meghan Fitzgerald | Director | Sale | 70.0K | $27.45 | $1.9M | SEC ↗ |
| Mar 19, 2026 | Eric Venker | President & Immunovant CEO | Sale | 200.0K | $28.24 | $5.6M | SEC ↗ |
| Mar 18, 2026 | Melissa B, Epperly | Director | Sale | 41.9K | $28.68 | $1.2M | SEC ↗ |
| Feb 24, 2026 | Frank Torti | President and Vant Chair | Sale | 3.0M | $27.35 | $82.0M | SEC ↗ |
| Feb 18, 2026 | Eric Venker | President & Immunovant CEO | Sale | 200.0K | $26.49 | $5.3M | SEC ↗ |
Showing the 25 most recent of 145 Form 4 filings for Roivant Sciences Ltd..
Most active ROIV insiders
- Eric Venker55 filings
- Rakhi Kumar20 filings
- Matthew Gline14 filings
- Mayukh Sukhatme8 filings
- Daniel Allen Gold7 filings
Ask anything about ROIV insider activity
Use Trabud's AI agent to query Roivant Sciences Ltd.'s Form 4 history in plain English — "Show me ROIV CEO purchases this year" or compare it against any other ticker.
Open the AI agentROIV insider trading FAQ
Are Roivant Sciences Ltd. insiders buying or selling?
In the last 12 months, Roivant Sciences Ltd. insiders reported 0 open-market purchases ($0) and 43 sales ($805.7M) — net selling of $805.7M. Since March 2022, Trabud has recorded 145 Form 4 filings for ROIV: 2 buys ($20.2M) and 143 sells ($2.2B). Over the full record that is net selling of $2.2B.
How many insiders trade ROIV stock?
18 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Roivant Sciences Ltd.. The most recent filing was accepted on Oct 5, 2026.
Where does Trabud get ROIV insider trading data?
All ROIV insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.